AdaptHealth (NASDAQ:AHCO) has received mixed analyst ratings over the past three months, with 2 bullish, 1 somewhat bullish, and 1 somewhat bearish. The average 12-month price target is now $9.88, down from $14.00, with a high estimate of $13.00 and a low of $6.50. Analysts from UBS, RBC Capital, B of A Securities, and Truist Securities have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. AdaptHealth's financials show a market cap below industry benchmarks, a revenue growth of 4.67%, a net margin of -77.8%, an ROE of -23.21%, an ROA of -9.15%, and a debt-to-equity ratio of 1.33.